Rhenman & Partners Asset Management’s Viking Therapeutics VKTX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.99M	Sell	128,000 -32,000	-20%	-$1.03M	0.47%	71
2026 Q1	$5.21M	Buy	160,000 +77,000	+93%	+$2.47M	0.64%	56
2025 Q4	$2.92M	Sell	83,000 -133,288	-62%	-$4.72M	0.27%	81
2025 Q3	$5.68M	Buy	216,288 +131,288	+154%	+$3.92M	0.63%	49
2025 Q2	$2.25M	Sell	85,000 -15,000	-15%	-$395K	0.28%	69
2025 Q1	$2.42M	Buy	100,000 +10,000	+11%	+$316K	0.28%	66
2024 Q4	$3.62M	Sell	90,000 -12,500	-12%	-$713K	0.37%	63
2024 Q3	$6.49M	Sell	102,500 -12,500	-11%	-$733K	0.53%	60
2024 Q2	$6.1M	Sell	115,000 -30,000	-21%	-$1.97M	0.59%	51
2024 Q1	$11.9M	Sell	145,000 -35,000	-19%	-$1.56M	1.13%	31
2023 Q4	$3.35M	Hold	180,000	–	–	0.33%	66
2023 Q3	$1.99M	Hold	180,000	–	–	0.21%	73
2023 Q2	$2.92M	Hold	180,000	–	–	0.31%	68
2023 Q1	$3.12M	Buy	+180,000	New	+$1.86M	0.34%	68
2020 Q2	–	Sell	-200,000	Closed	-$936K	–	96
2020 Q1	$936K	Hold	200,000	–	–	0.13%	79
2019 Q4	$1.6M	Hold	200,000	–	–	0.18%	80
2019 Q3	$1.38M	Sell	200,000 -91,499	-31%	-$680K	0.17%	77
2019 Q2	$2.42M	Buy	+291,499	New	+$2.49M	0.27%	72

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Rhenman & Partners Asset Management's VKTX Position: Q2 2026 in Review

Rhenman & Partners Asset Management reduced its Viking Therapeutics (VKTX) stake by 20% in Q2 2026, selling an estimated $1.03M and leaving 128,000 shares worth $4.99M. The position accounts for 0.47% of the portfolio, ranked #71.

Rhenman & Partners Asset Management first reported a position in VKTX in Q2 2019 and has held it in 18 quarters since. The position peaked at $11.9M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Rhenman & Partners Asset Management held 128,000 shares of Viking Therapeutics worth $4.99M as of Q2 2026.
Rhenman & Partners Asset Management sold 32,000 Viking Therapeutics shares in Q2 2026, an estimated $1.03M.
Viking Therapeutics made up 0.47% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #71 holding.
Rhenman & Partners Asset Management first reported a position in Viking Therapeutics in Q2 2019 and has held it in 18 quarters since.
Rhenman & Partners Asset Management's Viking Therapeutics position peaked at $11.9M in Q1 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.